MET inhibitor Compound 1( —— )

Catalog No. M10776 CAS No. 1208248-23-0

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Get Quotation Bulk Inquiry Add to Cart

Product Name

MET inhibitor Compound 1
Note

Research use only, not for human use.
Brief Description

A novel potent, selective orally bioavailable MET tyrosine kinase inhibitor with IC50 of <1 nM and 12 nM for unphosphorylated and phosphorylaed MET, respectively.
Description

A novel potent, selective orally bioavailable MET tyrosine kinase inhibitor with IC50 of <1 nM and 12 nM for unphosphorylated and phosphorylaed MET, respectively; demonstrates potent, broad spectrum activity against MET mutants (V1110I, H1112Y, L1195V, Y1235D, D1228H and M1250T) with IC50 of <1 nM-57 nM, and Y1230 mutants with moderate potency (IC50=25-280 nM); displays >50-fold selectivity in a panel of 130 kinases with exception of Fms and TrkA/B/C; inhibits MET-dependent tumor cell growth in vivo through decreasing phosphorylaed MET.
In Vitro

——
In Vivo

——
Synonyms

——
Pathway

Angiogenesis
Target

c-Met/HGFR
Recptor

c-Met/HGFR
Research Area

——
Indication

——

CAS Number

1208248-23-0
Formula Weight

449.426
Molecular Formula

C21H17F2N9O
Purity

>98% (HPLC)
Solubility

——
SMILES

——
Chemical Name

N-(6-(difluoro(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)methyl)imidazo[1,2-b]pyridazin-2-yl)cyclopropanecarboxamide

1. Farrell PJ, et al. Mol Cancer Ther. 2017 Jul;16(7):1269-1278.

Calculator

molnova catalog